334 related articles for article (PubMed ID: 34445144)
1. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies.
Martin P; Reeder T; Sourbron J; de Witte PAM; Gammaitoni AR; Galer BS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445144
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine acts as a positive modulator of sigma-1 receptors.
Martin P; de Witte PAM; Maurice T; Gammaitoni A; Farfel G; Galer B
Epilepsy Behav; 2020 Apr; 105():106989. PubMed ID: 32169824
[TBL] [Abstract][Full Text] [Related]
3. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Frampton JE
Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
Sills GJ
Ther Adv Neurol Disord; 2023; 16():17562864231191000. PubMed ID: 37655228
[TBL] [Abstract][Full Text] [Related]
5. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
Epilepsia Open; 2024 Jul; ():. PubMed ID: 38962968
[TBL] [Abstract][Full Text] [Related]
6. Fenfluramine: a plethora of mechanisms?
Sourbron J; Lagae L
Front Pharmacol; 2023; 14():1192022. PubMed ID: 37251322
[TBL] [Abstract][Full Text] [Related]
7. Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.
Balagura G; Cacciatore M; Grasso EA; Striano P; Verrotti A
CNS Drugs; 2020 Oct; 34(10):1001-1007. PubMed ID: 32875491
[TBL] [Abstract][Full Text] [Related]
8. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
9. The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results.
Johannessen Landmark C; Potschka H; Auvin S; Wilmshurst JM; Johannessen SI; Kasteleijn-Nolst Trenité D; Wirrell EC
Epilepsia; 2021 Apr; 62(4):857-873. PubMed ID: 33638459
[TBL] [Abstract][Full Text] [Related]
10. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
11. Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study.
Tarquinio D; Wheless JW; Segal EB; Misra SN; Rabinowicz AL; Carrazana E
J Child Neurol; 2023 May; 38(6-7):389-393. PubMed ID: 37455404
[TBL] [Abstract][Full Text] [Related]
12. New and emerging pharmacologic treatments for developmental and epileptic encephalopathies.
Vasquez A; Buraniqi E; Wirrell EC
Curr Opin Neurol; 2022 Apr; 35(2):145-154. PubMed ID: 35102126
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Selective 5-HT
Silenieks LB; Carroll NK; Van Niekerk A; Van Niekerk E; Taylor C; Upton N; Higgins GA
ACS Chem Neurosci; 2019 Jul; 10(7):3284-3295. PubMed ID: 31082204
[TBL] [Abstract][Full Text] [Related]
14. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
Schoonjans AS; Ceulemans B
Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
[TBL] [Abstract][Full Text] [Related]
15. Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo.
Martin P; Maurice T; Gammaitoni A; Farfel G; Boyd B; Galer B
Epilepsy Behav; 2022 Feb; 127():108526. PubMed ID: 35007961
[TBL] [Abstract][Full Text] [Related]
16. Sigma-1 receptor and seizures.
Vavers E; Zvejniece L; Dambrova M
Pharmacol Res; 2023 May; 191():106771. PubMed ID: 37068533
[TBL] [Abstract][Full Text] [Related]
17. Genetic Background of Epilepsy and Antiepileptic Treatments.
Borowicz-Reutt K; Czernia J; Krawczyk M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003469
[TBL] [Abstract][Full Text] [Related]
18. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
[TBL] [Abstract][Full Text] [Related]
19. Developmental and epileptic encephalopathies: recognition and approaches to care.
Raga S; Specchio N; Rheims S; Wilmshurst JM
Epileptic Disord; 2021 Feb; 23(1):40-52. PubMed ID: 33632673
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in Dravet syndrome: a targeted literature review.
Strzelczyk A; Schubert-Bast S
Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
